Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Zandelisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MEI and Kyowa Kirin to discontinue development of zandelisib outside Japan
    MEI and Kyowa Kirin to discontinue development of zandelisib outside Japan

    07 Dec 2022

    // PHARMACEUTICAL-TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/mei-kyowa-kirin-zandelisib/

    PHARMACEUTICAL-TECHNOLOGY
    07 Dec 2022
    Share Share
    MEI Pharma & Kyowa Kirin Announce Discontinuation of Zandelisib Outside of Japan
    MEI Pharma & Kyowa Kirin Announce Discontinuation of Zandelisib Outside of Japan

    06 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221205005800/en/MEI-Pharma-and-Kyowa-Kirin-Announce-Discontinuation-of-Zandelisib-Development-Outside-of-Japan-Following-Recent-FDA-Meeting

    BUSINESSWIRE
    06 Dec 2022
    Share Share
    MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    01 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220801005185/en

    BUSINESSWIRE
    01 Aug 2022
    Share Share
    MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology
    MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology

    18 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220718005236/en

    BUSINESSWIRE
    18 Jul 2022
    Share Share
    MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at ASCO 2022
    MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at ASCO 2022

    04 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220604005001/en

    BUSINESSWIRE
    04 Jun 2022
    Share Share
    FDA rebuffs MEI, Kyowa Kirin as another cancer drug class draws scrutiny
    FDA rebuffs MEI, Kyowa Kirin as another cancer drug class draws scrutiny

    26 Mar 2022

    // Jonathan Gardner BIOPHARMADIVE

    https://www.biopharmadive.com/news/mei-kyowa-kirin-zandelisib-FDA-new-trial-accelerated-approval/621042/

    Jonathan Gardner BIOPHARMADIVE
    26 Mar 2022
    Share Share